The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease.

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even ...

Shares of drugmaker Bristol Myers Squibb were up almost 6% as of Wednesday afternoon, despite a delay in a late-stage study ...

Investing.com -- Bristol Myers Squibb (NYSE:BMY) stock rose 1.5% Wednesday after the company announced it will continue its ADEPT-2 Phase 3 study for psychosis associated with Alzheimer’s disease ...

Bristol-Myers Squibb shares rallied Wednesday after the drugmaker delayed the release of eagerly awaited clinical-trial results for a potential Alzheimer’s disease treatment. Analysts said investors ...

Bristol-Myers Squibb shares gained after the company announced that it will enroll additional patients in the ADEPT-2 study.

New Jersey-based Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical giant focused on discovering, developing ...

Wondering if Bristol-Myers Squibb is a bargain or overpriced? Let’s dig into what’s behind the numbers so you can decide with ...

Explore the exciting world of Bristol Meyers Squibb (NYSE: BMY) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into ...

One particularly appealing dividend stock right now is Bristol Myers Squibb (NYSE: BMY). It yields 5.4%, which is an ...

This was the stock's third consecutive day of losses.